Welcome to our dedicated page for Elicio Therapeutics news (Ticker: ELTX), a resource for investors and traders seeking the latest updates and insights on Elicio Therapeutics stock.
Elicio Therapeutics, Inc. (ELTX) is a clinical-stage biotechnology company pioneering lymph node-targeted immunotherapies through its proprietary AMP platform. This dedicated news hub provides investors and industry observers with timely updates on ELTX's progress in developing novel cancer treatments.
Access official press releases, clinical trial milestones, and corporate developments related to ELTX's innovative pipeline. Track updates on KRAS-targeted vaccines, AMP platform advancements, and strategic collaborations. Our curated collection includes regulatory filings, peer-reviewed research highlights, and financial disclosures essential for informed analysis.
Key focus areas include clinical progress updates, partnership announcements, intellectual property developments, and scientific presentations. This resource serves investors seeking to monitor ELTX's position in the competitive immunotherapy landscape while staying informed about its novel approach to enhancing T cell responses against aggressive cancers.
Bookmark this page for streamlined access to verified ELTX developments. Check regularly for updates on the company's mission to transform cancer treatment through precision immune system engagement.
Elicio Therapeutics reported preliminary data from its AMPLIFY-7P Phase 1a study of ELI-002 7P, an investigational therapeutic cancer vaccine. Administered as a monotherapy at the Phase 2 dose of 4.9mg AMP-peptide, ELI-002 7P shows promising disease-free survival (DFS) data in pancreatic ductal adenocarcinoma patients.
As of May 24, 2024, the study includes 14 patients with minimal residual disease and a median follow-up of 29.1 weeks. The median DFS has not been reached for patients receiving the 4.9mg dose, compared to 12.6 weeks for those on the 1.4mg dose. Patients showing tumor biomarker reduction and strong T cell response had no progression events, whereas those without biomarker response had a median DFS of 11.0 weeks.
Elicio plans further updates on the AMPLIFY Phase 1 trials later in 2024, with a Phase 2 interim analysis expected in Q1 2025.
Elicio Therapeutics (Nasdaq: ELTX), a biotechnology company specializing in immunotherapies for cancer, announced on June 18, 2024, the issuance of 5,400 inducement stock options to two new employees. These options, granted on June 17, 2024, align with Nasdaq Listing Rule 5635(c)(4) and were approved by the board's Compensation Committee under the 2024 Inducement Incentive Award Plan. The options are priced at $7.98 each, reflecting the closing price on the grant date. Vesting occurs over four years with 25% vesting on the first anniversary of the employees' start dates, and the remaining vesting monthly thereafter, contingent on continued employment.
Elicio Therapeutics revealed preliminary data from their AMPLIFY-7P Phase 1a study of ELI-002 7P at the ASCO 2024 Annual Meeting. The cancer vaccine candidate, targeting mKRAS-driven solid tumors, showed promising results. ELI-002 7P was well tolerated and induced a significant (~100x) mKRAS-specific T cell response in all enrolled patients.
Key findings included CD8+ and CD4+ responses in 66.7% of patients at the 4.9 mg dose, and tumor biomarker reductions in 71% of evaluable patients. Antigen-spreading, targeting non-immunizing tumor neoantigens, was observed in all patients at the 4.9 mg dose. The study supports further development, with the recommended Phase 2 dose being 10.0 mg AMP-CpG-7909 with 4.9 mg AMP-Peptides 7P.
Elicio Therapeutics (Nasdaq: ELTX) reported its Q1 2024 financial results and provided corporate updates on its lead cancer vaccine programs, ELI-002 2P and ELI-002 7P.
Q1 financial highlights include a net loss of $11.8 million, increased R&D expenses of $7.6 million, and G&A expenses of $2.7 million. Cash reserves stood at $11.9 million as of March 31, 2024.
ELI-002 2P data was published in Nature Medicine, showing promising immunogenicity and safety. ELI-002 7P is in Phase 2 trials, with preliminary Phase 1 data to be presented at ASCO in June 2024.
Upcoming milestones include completing Phase 2 enrollment for ELI-002 7P by Q4 2024 and providing updated data for ELI-002 2P in Q4 2024.
FAQ
What is the current stock price of Elicio Therapeutics (ELTX)?
What is the market cap of Elicio Therapeutics (ELTX)?
